(S,R,S)-AHPC-PEG3-NH2

Background Introduction

(S,R,S)-AHPC-PEG3-NH2 is a specialized E3 ligase ligand-linker conjugate widely used in the development of PROTACs (Proteolysis Targeting Chimeras). PROTAC technology is revolutionizing targeted protein degradation by leveraging the ubiquitin-proteasome system to eliminate disease-causing proteins, offering a promising therapeutic strategy for various diseases including cancer, neurodegenerative disorders, and immune conditions.

Mechanism

(S,R,S)-AHPC-PEG3-NH2 functions as a bifunctional molecule, where the AHPC moiety selectively binds to the Von Hippel-Lindau (VHL) E3 ligase. The PEG3 linker provides optimal spatial orientation and flexibility, enabling the other end of the molecule (the amine group, NH2) to be conjugated with a ligand targeting the protein of interest (POI). When incorporated in a PROTAC structure, this conjugate recruits the VHL E3 ligase to the POI, facilitating its ubiquitination and subsequent degradation by the proteasome.

Applications

(S,R,S)-AHPC-PEG3-NH2 is a versatile building block for the synthesis of novel PROTAC molecules targeting a wide range of undruggable proteins. It is ideal for use in drug discovery and development, mechanistic studies of protein degradation, and generation of chemical biology tools. Researchers leverage (S,R,S)-AHPC-PEG3-NH2 to develop selective protein degraders, enabling advanced therapeutic strategies and functional studies in oncology, neurology, and immunology.

• PEG3 linker provides improved aqueous solubility and enhanced pharmacokinetic properties for optimal PROTAC performance.
• Amine-terminated ligand is precisely designed for efficient conjugation and targeted recruitment of the VHL E3 ligase.

The E3 Ligase Ligand-Linker Conjugate (S,R,S)-AHPC-PEG3-NH2 plays a crucial role in the development of PROTACs by facilitating targeted protein degradation, offering advantages such as enhanced selectivity and reduced off-target effects. The following provides a detailed description of this molecule, including its linker, ligand, and suitable target protein ligands.

Linker: The linker in (S,R,S)-AHPC-PEG3-NH2 is a PEG3 chain, known for its moderate length and flexible nature, which enhances solubility and facilitates optimal spatial orientation. Its non-cleavable nature ensures stability, maintaining the integrity of the conjugate during cellular processes.

Ligand: The ligand component is based on AHPC, a derivative of thalidomide, which is structurally designed to bind selectively to the CRBN E3 ligase. This specificity is crucial for directing the ubiquitination machinery towards the target protein, ensuring precise degradation.

Reactive Site: The reactive site of (S,R,S)-AHPC-PEG3-NH2 features a terminal amine group, which is primed for coupling with carboxylic acid-containing target protein ligands. Recommended reaction types include amide bond formation, which is efficient and widely used in conjugate chemistry.

Recommended Target Protein Ligand: The compatible warhead for this molecule should ideally possess a carboxylic acid functional group, facilitating robust amide bond formation with the amine terminus. This configuration allows for the effective recruitment of the target protein to the E3 ligase, promoting its ubiquitination and subsequent proteasomal degradation, thereby offering a strategic approach for studying protein function and regulation in cellular contexts.